Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Overview 6
Therapeutics Development 7
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Stage of Development 7
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Therapy Area 8
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Indication 9
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Companies 12
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Universities/Institutes 14
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Companies Involved in Therapeutics Development 21
Affichem SA 21
Bristol-Myers Squibb Company 22
Vitae Pharmaceuticals, Inc. 23
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Drug Profiles 24
AF-122 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
BMS-779788 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
SR-9238 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
VTP-38543 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
VTP-4 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Dormant Projects 29
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Discontinued Products 30
Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Featured News & Press Releases 31
Dec 29, 2015: Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis 31
Dec 10, 2015: Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients 31
Apr 03, 2015: AFFICHEM announces the presentation of an oral communication at the 35th Annual Meeting of the French Society of Hematology in Paris 32
Dec 06, 2014: AFFICHEM announces the presentation of a poster at the 56th Annual Meeting of the American Society of Hematology in San Francisco 32
Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease 32
Sep 06, 2012: Vitae Pharma Announces Promising Data On Atherosclerotic Drug VTP-4 At Frontiers In Lipid Biology Conference 33
Nov 29, 2007: Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Achievement Of Liver X Receptor Agonist Development Milestone 34
Dec 06, 2005: Exelixis And Bristol-Myers Squibb Signs New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Affichem SA, H1 2016 21
Pipeline by Bristol-Myers Squibb Company, H1 2016 22
Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 23
Dormant Projects, H1 2016 29
Discontinued Products, H1 2016 30

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Routes of Administration, H1 2016 18
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20